Floatz logo

Panobinostat

HLRCC

National Cancer Institute (NCI)Small moleculePhase 2Active
B
56/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
41/ 100
Competitive Position
95/ 100

Competitive context

7 Active assets in the HLRCC cohort.

Asset / SponsorPhaseRating
Irinotecan
National Cancer Institute (NCI)
Phase 2B
(+)-VINCRISTINE
National Cancer Institute (NCI)
Phase 2B
Glutamine
University of Texas Southwestern Medical Center
N/AD
Lactate
University of Texas Southwestern Medical Center
N/AD
ACETIC-1-13C ACID
University of Texas Southwestern Medical Center
N/AD
GLUCOSE, ANHYDROUS
University of Texas Southwestern Medical Center
N/AD
13C-Fructose
University of Texas Southwestern Medical Center
N/AD

Same molecule, other indications

Panobinostat is also rated in:

Hodgkins lymphomaDormant
BB
Indicative ·
68 / 100
View asset →
Non-Small Cell Lung CancerDormant
BB
Indicative ·
66 / 100
View asset →
chronic lymphocytic leukemia/small lymphocytic lymphomaDormant
BB
Indicative ·
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →